Abstract: The present invention provides a pressure casting method of a magnesium alloy. In the method, a molten magnesium alloy is cooled to form a partially molten state containing a solid-phase, and the partially molten state is further cooled to form a solid-phase granularly crystallized solid material. The solid material is partially-melted and pressure cast into a mold by a molding machine. A ratio of primary crystals in said solid material is set to 55 to 65%. The solid material is partially-melted in a solid-phase and liquid-phase coexisting state at a selected heating temperature so that a semi-solid having thixotropic properties and having the size of a main solid phase of 50 to 250 ?m and a solid-phase ratio of 30 to 70% is formed. The semi-solid is pressure cast into a mold through a nozzle while maintaining the semi-solid state to form metal products having a ratio of primary crystals of 20 to 50%.

Abstract: A car having a rotatable wheel, the car being able to run by rotating the wheel, the car having a leg used by the car for walking, and an attitude stabilization section for stabilizing an attitude of the car.

Abstract: There is provided a process for producing an aromatic hydroxycarboxylic acid which is capable of suppressing the formation of by-products and enhancing the selectivity of the intended product and is free from any purifying step. The process is characterized in that it is obtained by reacting an alkali metal salt of an aromatic hydroxy compound and carbon dioxide in a non-proton polar solvent in the presence of a solid basic catalyst.

Abstract: A car includes a car body having a bottom portion, a wheel that is rotatable, and a supporting member for supporting the wheel, the supporting member being provided to the bottom portion. At least eight pairs of the wheel and the supporting member are provided. The supporting member has a first supporting portion for supporting the wheel rotatably, a second supporting portion for supporting the first supporting portion so that a direction of the wheel supported by the first supporting portion can be changed, and a turning portion that is rotatable about a rotation axis with its axial direction along a direction orthogonal to the bottom portion, the turning portion being provided to the bottom portion. The turning portion supports the second supporting portion so that a distance between the wheel and the bottom portion can be changed, and a position of the wheel can be moved by a rotation of the turning portion in a state that the distance is maintained.

Abstract: A satellite system includes a signal source located on a surface of the earth, a surface of water, or in air; an orbiting satellite for measuring a position of the signal source, having a GPS receiver which receives a GPS signal from a GPS satellite system to measure the position of the orbiting satellite, a frequency measuring device for receiving the radio wave signal emitted from the signal source to measure the frequency thereof, a memory for storing frequency data and position data, and a transmitting device for transmitting the data stored in the memory toward the earth; and a ground station, having a signal receiving device for receiving the data transmitted from the orbiting satellite, including a computer for calculating the position of the signal source based on the data received by the signal receiving device.

Abstract: A pharmaceutical composition comprising a capped oligonucleotide capable of binding to a PB2 protein of an influenza virus RNA polymerase, and a pharmaceutically acceptable carrier or dilute, said capped oligonucleotide having a structure of the formula (I): m7GpppXpY  (I) wherein ppp is a triphosphate bridge, p is a monophosphate bridge, m7G is 7-methylguanosine group binding at 5′ end thereof to said ppp, X is a 2′-O-methyl guanosine group or guanosine group, said 2′-O-methyl guanosine group or guanosine group binds at a 5′ end thereof to said ppp, and at a 3′ end thereof to said p, and Y is an oligoribonucleotide moiety binding at 5′ end thereof to said p, and having 5 to 11 bases is disclosed. The pharmaceutical composition can inhibit a protein expression of an influenza virus.